Source comparison
TB-500 Studied Sports Injury: Research Dosing vs Real-World Application
TB-500 studied sports injury protocols in research settings use dosing regimens that are body-weight-adjusted and specific to the injury model. In equine studies, typical dosing ranges from 2.5 mg to 10 mg per horse (approximately 0.005–0.02 mg/kg for a 500 kg
This comparison does not assign a generated winner or score.
- TB-500 studied sports injury protocols in research settings use dosing regimens that are body-weight-adjusted and specific to the injury model. In equine studies, typical dosing ranges from 2.5 mg to 10 mg per horse (approximately 0.005–0.02 mg/kg for a 500 kg horse), administered subcutaneously or intramuscularly once or twice weekly for 4–6 weeks. Rodent models scale higher relative to body weight. 6 mg/kg is common in murine studies, which would translate to approximately 420 mg for a 70 kg human if the scaling held directly (it doesn't. Pharmacokinetics differ across species).
- No large-scale human clinical trials have been published establishing optimal TB-500 dosing for sports injuries specifically. The existing human data comes from safety trials for cardiac and dermal wound applications, where Tβ4 was administered at doses up to 1,800 mg intravenously over multiple weeks without dose-limiting toxicity. These trials weren't designed to measure sports injury recovery outcomes, so effect size in human athletic populations remains undocumented in peer-reviewed literature.
- Researchers using TB-500 for in vitro or animal model work source the peptide from specialized research suppliers. Our Real Peptides catalog includes high-purity thymosin beta-4 formulations synthesized with exact amino-acid sequencing and third-party purity verification. Critical controls for any laboratory studying peptide-mediated tissue repair mechanisms. The compound is stable when lyophilized and stored at −20°C; once reconstituted with bacteriostatic water, it must be refrigerated at 2–8°C and used within 28 days to maintain structural integrity.
- The dosing gap between published research and off-label human use is substantial. TB-500 studied sports injury models use precise dosing tied to injury type and body weight, administered under controlled conditions with outcome measurement. That structure doesn't exist in unregulated settings, where dosing is often empirical and outcomes are self-reported rather than objectively measured.